Tarsus Pharmaceuticals (TARS) shares jumped after stronger-than-expected sales growth from Xdemvy, its prescription treatment for Demodex blepharitis. The company also announced it is preparing mid-stage trials for new pipeline therapies.

Tarsus Pharmaceuticals has been on an impressive run, with a 22.6% share price return over the past month and more than doubling total shareholder return at 100.8% in the last year. Recent surges reflect optimism around Xdemvy’s commercial momentum and anticipation for new clinical programs. It is clear that investor sentiment is building rather than fading.

If this kind of growth story has you thinking about other healthcare disruptors, it could be the perfect time to explore See the full list for free.

With shares now trading near analyst targets after a year of rapid gains, the key question is whether investor enthusiasm has pushed Tarsus Pharmaceuticals ahead of its fundamentals, or if there is still room for upside from here.

Most Popular Narrative: 8% Undervalued

Compared to Tarsus Pharmaceuticals’ last close of $69.75, the most followed narrative sets its fair value at $76, suggesting the shares have room left to run. This perspective is grounded in bold growth assumptions and a rapidly expanding market opportunity for its lead therapy.

Accelerated patient and physician adoption of XDEMVY, driven by a robust direct-to-consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top-line revenue growth. Strong demographic tailwinds from an aging population and higher prevalence of chronic conditions such as Demodex blepharitis are expected to enlarge Tarsus' core addressable market, fueling long-term sustainable revenue increases.

Curious what revenue and margin leaps underpin this target? The narrative hinges on a transformation in Tarsus’s future earnings power and market reach. It is driven by aggressive projections that rival some of the fastest growth stories in healthcare. The numbers behind the optimism might surprise you.

Result: Fair Value of $76 (UNDERVALUED)

However, if Xdemvy’s adoption slows or if rising costs outpace revenue, Tarsus’s long-term growth story could encounter significant hurdles.

Another View: Asking if the Price Still Makes Sense

Looking at traditional price-to-sales ratios, Tarsus Pharmaceuticals trades at 10x sales, which is more than double the US Pharmaceuticals industry average of 4.8x and above its own fair ratio of 7.8x. While its price is lower than some peers, this premium means investors are paying extra for its future growth story. This raises the stakes if expectations are not met. Is the current optimism justified, or does this multiple leave little margin for error?

Build Your Own Tarsus Pharmaceuticals Narrative

If you see the story differently, or want to explore the figures firsthand, it takes just a few minutes to piece together your own perspective. Do it your way

A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Don’t let fresh opportunities pass you by. Uncover standout investment trends across the market and sharpen your strategy with powerful stock lists tailored to different themes:

• Secure your portfolio's income potential as you browse these 19 dividend stocks with yields > 3% with yields above 3% and a record of stability.
• Spot game-changing firms in artificial intelligence by tracking these 26 AI penny stocks before the next breakthrough headlines hit.
• Get ahead of the crowd and evaluate these 3572 penny stocks with strong financials showing robust financials that might be tomorrow’s big winners.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.